Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Current Leases (2023)

Insight Molecular Diagnostics (IMDX) has disclosed Current Leases for 1 consecutive years, with $628000.0 as the latest value for Q4 2023.

  • Quarterly Current Leases changed N/A to $628000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $628000.0 through Dec 2023, changed N/A year-over-year, with the annual reading at $628000.0 for FY2023, N/A changed from the prior year.
  • Current Leases hit $628000.0 in Q4 2023 for Insight Molecular Diagnostics.
  • In the past five years, Current Leases ranged from a high of $628000.0 in Q4 2023 to a low of $628000.0 in Q4 2023.